Loading clinical trials...
Loading clinical trials...
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Conditions
Interventions
Cyclophosphamide
Locations
1
United States
UAB Bone Marrow Transplantation and Cellular Therapy Program
Birmingham, Alabama, United States
Start Date
August 27, 2013
Primary Completion Date
April 1, 2022
Completion Date
April 1, 2022
Last Updated
September 30, 2022
NCT07249528
NCT04570423
NCT06303193
NCT06735690
NCT05564390
NCT00131014
Lead Sponsor
University of Alabama at Birmingham
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions